M. Maio
The evolving role of immunotherapy in cancer treatment

A. Rossi
Appropriate response evaluation criteria

F. Perrone
Methodology of clinical trials

P. Ascierto
Immunotherapy of melanoma: a successful example

M. Barberis
Predictive biomarkers in immunotherapy: pitfall and reality

A. Passaro
Immunotherapy - related toxicity and its management

J. Brahmer
Anti PD-1: phase I-II trials

N.A. Rizvi
Anti PD-1: phase III studies

B. Besse
The role of anti PD-L1

E. Felip
Combination of immunotherapy and targeted therapies in biomarkers-driven disease

Discussion
Advanced NSCLC: building together a treatment algorithm in the check-point inhibitors era